Keywords: Novo Nordisk, Degludec, Type 2 diabetes, Dosing, EASD
Data show Novo Nordisk’s ultra-long-acting insulin degludec can be flexibly dosed
Article | 15 September 2011
Danish insulin giant Novo Nordisk’s (NVO: N) ultra-long-acting insulin degludec, an investigational basal insulin, showed significant blood sugar ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
